AstraZeneca teams up with Oxford U. on COVID-19 vaccine

AstraZeneca (NYSE:AZN) will collaborate with the University of Oxford on the development and distribution of the latter’s recombinant adenovirus vaccine candidate, ChAdOx1 nCoV-19, for the prevention of COVID-19 infection.

Phase 1 studies commenced last week in healthy volunteers with results expected next month. Later stage trials should launch mid-year.

The vaccine is designed to generate a strong immune response from a single dose.

Shares up 4% premarket on light volume.

https://seekingalpha.com/news/3566711-astrazeneca-teams-up-oxford-u-on-covidminus-19-vaccine